Macrophage-Biomimetic Nanoparticles Ameliorate Ulcerative Colitis through Reducing Inflammatory Factors Expression

Background and Aims: Inflammatory mediator S100A9 is dramatically elevated in ulcerative colitis and correlates with disease severity. S100A9 is a potential molecule to target for the treatment of colitis, but to date, there is no effective targeting method. The aim of this study was to develop a sa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhengshuo Li, Xiaoyue Zhang, Can Liu, Qiu Peng, Yangge Wu, Yuqing Wen, Run Zheng, Qun Yan, Jian Ma
Formato:	article
Lenguaje:	EN
Publicado:	Karger Publishers 2021
Materias:	ulcerative colitis s100a9 inhibitor biomimetic nanoparticles drug delivery system Medicine R Internal medicine RC31-1245
Acceso en línea:	https://doaj.org/article/5499fbc86a49406aa14c6873ff350cd5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5499fbc86a49406aa14c6873ff350cd5
record_format	dspace
spelling	oai:doaj.org-article:5499fbc86a49406aa14c6873ff350cd52021-11-25T07:47:20ZMacrophage-Biomimetic Nanoparticles Ameliorate Ulcerative Colitis through Reducing Inflammatory Factors Expression1662-811X1662-812810.1159/000519363https://doaj.org/article/5499fbc86a49406aa14c6873ff350cd52021-11-01T00:00:00Zhttps://www.karger.com/Article/FullText/519363https://doaj.org/toc/1662-811Xhttps://doaj.org/toc/1662-8128Background and Aims: Inflammatory mediator S100A9 is dramatically elevated in ulcerative colitis and correlates with disease severity. S100A9 is a potential molecule to target for the treatment of colitis, but to date, there is no effective targeting method. The aim of this study was to develop a safe and effective nano-delivery system targeting S100A9 and to evaluate its therapeutic efficacy in ulcerative colitis mouse model. Methods: We designed an oral nano-delivery system using poly (lactic acid-glycolic acid) (PLGA)-loaded S100A9 inhibitor tasquinimod to synthesize PLGA-TAS nanoparticles. TLR4-overexpressing macrophage membranes (MMs) were used to wrap the nanoparticles to make MM-PLGA-TAS, which allowed the nanoparticles to acquire the ability to specifically enrich the colitis region. Results: MM-PLGA-TAS was endocytosed by inflammatory phenotype RAW264.7 cells in vitro and can efficiently enrich in inflamed mouse colitis tissue in vivo. A chemically induced ulcerative colitis mouse model was used to evaluate the therapeutic effect of oral MM-PLGA-TAS. MM-PLGA-TAS significantly alleviated the symptoms of ulcerative colitis, and mechanically, MM-PLGA-TAS achieved immunomodulatory and suppressive effects by reducing S100a9 and other cytokines in the colitis region. Conclusion: We describe a convenient, orally targeted colitis drug delivery system that cures the disease in ulcerative colitis mice. This system substantially increases drug accumulation in inflamed colonic tissue, reduces the risk of systemic exposure, and is a promising therapeutic approach against ulcerative colitis.Zhengshuo LiXiaoyue ZhangCan LiuQiu PengYangge WuYuqing WenRun ZhengQun YanJian MaKarger Publishersarticleulcerative colitiss100a9 inhibitorbiomimetic nanoparticlesdrug delivery systemMedicineRInternal medicineRC31-1245ENJournal of Innate Immunity, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ulcerative colitis s100a9 inhibitor biomimetic nanoparticles drug delivery system Medicine R Internal medicine RC31-1245
spellingShingle	ulcerative colitis s100a9 inhibitor biomimetic nanoparticles drug delivery system Medicine R Internal medicine RC31-1245 Zhengshuo Li Xiaoyue Zhang Can Liu Qiu Peng Yangge Wu Yuqing Wen Run Zheng Qun Yan Jian Ma Macrophage-Biomimetic Nanoparticles Ameliorate Ulcerative Colitis through Reducing Inflammatory Factors Expression
description	Background and Aims: Inflammatory mediator S100A9 is dramatically elevated in ulcerative colitis and correlates with disease severity. S100A9 is a potential molecule to target for the treatment of colitis, but to date, there is no effective targeting method. The aim of this study was to develop a safe and effective nano-delivery system targeting S100A9 and to evaluate its therapeutic efficacy in ulcerative colitis mouse model. Methods: We designed an oral nano-delivery system using poly (lactic acid-glycolic acid) (PLGA)-loaded S100A9 inhibitor tasquinimod to synthesize PLGA-TAS nanoparticles. TLR4-overexpressing macrophage membranes (MMs) were used to wrap the nanoparticles to make MM-PLGA-TAS, which allowed the nanoparticles to acquire the ability to specifically enrich the colitis region. Results: MM-PLGA-TAS was endocytosed by inflammatory phenotype RAW264.7 cells in vitro and can efficiently enrich in inflamed mouse colitis tissue in vivo. A chemically induced ulcerative colitis mouse model was used to evaluate the therapeutic effect of oral MM-PLGA-TAS. MM-PLGA-TAS significantly alleviated the symptoms of ulcerative colitis, and mechanically, MM-PLGA-TAS achieved immunomodulatory and suppressive effects by reducing S100a9 and other cytokines in the colitis region. Conclusion: We describe a convenient, orally targeted colitis drug delivery system that cures the disease in ulcerative colitis mice. This system substantially increases drug accumulation in inflamed colonic tissue, reduces the risk of systemic exposure, and is a promising therapeutic approach against ulcerative colitis.
format	article
author	Zhengshuo Li Xiaoyue Zhang Can Liu Qiu Peng Yangge Wu Yuqing Wen Run Zheng Qun Yan Jian Ma
author_facet	Zhengshuo Li Xiaoyue Zhang Can Liu Qiu Peng Yangge Wu Yuqing Wen Run Zheng Qun Yan Jian Ma
author_sort	Zhengshuo Li
title	Macrophage-Biomimetic Nanoparticles Ameliorate Ulcerative Colitis through Reducing Inflammatory Factors Expression
title_short	Macrophage-Biomimetic Nanoparticles Ameliorate Ulcerative Colitis through Reducing Inflammatory Factors Expression
title_full	Macrophage-Biomimetic Nanoparticles Ameliorate Ulcerative Colitis through Reducing Inflammatory Factors Expression
title_fullStr	Macrophage-Biomimetic Nanoparticles Ameliorate Ulcerative Colitis through Reducing Inflammatory Factors Expression
title_full_unstemmed	Macrophage-Biomimetic Nanoparticles Ameliorate Ulcerative Colitis through Reducing Inflammatory Factors Expression
title_sort	macrophage-biomimetic nanoparticles ameliorate ulcerative colitis through reducing inflammatory factors expression
publisher	Karger Publishers
publishDate	2021
url	https://doaj.org/article/5499fbc86a49406aa14c6873ff350cd5
work_keys_str_mv	AT zhengshuoli macrophagebiomimeticnanoparticlesameliorateulcerativecolitisthroughreducinginflammatoryfactorsexpression AT xiaoyuezhang macrophagebiomimeticnanoparticlesameliorateulcerativecolitisthroughreducinginflammatoryfactorsexpression AT canliu macrophagebiomimeticnanoparticlesameliorateulcerativecolitisthroughreducinginflammatoryfactorsexpression AT qiupeng macrophagebiomimeticnanoparticlesameliorateulcerativecolitisthroughreducinginflammatoryfactorsexpression AT yanggewu macrophagebiomimeticnanoparticlesameliorateulcerativecolitisthroughreducinginflammatoryfactorsexpression AT yuqingwen macrophagebiomimeticnanoparticlesameliorateulcerativecolitisthroughreducinginflammatoryfactorsexpression AT runzheng macrophagebiomimeticnanoparticlesameliorateulcerativecolitisthroughreducinginflammatoryfactorsexpression AT qunyan macrophagebiomimeticnanoparticlesameliorateulcerativecolitisthroughreducinginflammatoryfactorsexpression AT jianma macrophagebiomimeticnanoparticlesameliorateulcerativecolitisthroughreducinginflammatoryfactorsexpression
_version_	1718413617483743232

Macrophage-Biomimetic Nanoparticles Ameliorate Ulcerative Colitis through Reducing Inflammatory Factors Expression

Ejemplares similares